In semaglutides case: Novo Nordisk obtained a genus patent covering semaglutide as a compound, with the usual 20year protection.[19][20] Later, it filed a second patent on a closely related version intended to prolong exclusivity, along with a series of secondary patents on formulations and delivery devices.[21][14] The Delhi High Court, examining Novos suit against Indian companies like Dr Reddys, held that this second patent amounted to double patenting and evergreening , which is barred under Indias Patents Act (Section 3(d)).[20][22][19] Because India explicitly prohibits evergreening, the court refused to block Indian firms from manufacturing and exporting semaglutide while maintaining restrictions on incountry sales tied to remaining patent issues.[23][20] Key point: Courts in India have openly described parts of Novos semaglutide strategy as evergreeningextending monopoly protection beyond what a single invention normally deserves

doi: 10.3389/fnut.2023.1134162 Received 30 December 2022 Accepted 22 June 2023 Published 20 July 2023 Volume 10 - 2023 Edited by Xiaoping Yang, Hunan Normal University, China Reviewed by Lorenzo Lorusso, ASST Lecco, Italy
Nicotinamide (niacinamide): Found in supplements and foods
This is skincare with experience
Small, consistent improvementsmore nutrient-dense foods, regular movement, better sleepcan make a measurable difference